Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma

被引:29
|
作者
McCaughan, Georgia J. B. [3 ]
Fulham, Michael J. [1 ,3 ]
Mahar, Annabelle [3 ]
Soper, Judy [3 ,4 ]
Hong, Angela M. [1 ,2 ]
Stalley, Paul D. [3 ]
Tattersall, Martin H. N. [1 ,2 ]
Bhadri, Vivek A. [1 ,2 ]
机构
[1] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[2] Chris OBrien Lifehouse, 119-143 Missenden Rd, Camperdown, NSW 2050, Australia
[3] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia
[4] Specialist Magnet Resonance Imaging, Newton, NSW, Australia
来源
关键词
Ewing sarcoma; Immunotherapy; Anti-programmed cell death-1 antibody; Case report; GENOMIC INSTABILITY; CANCER; SURVIVAL; EXPERIENCE; NIVOLUMAB; ANTIBODY; THERAPY; REPAIR; FAMILY; TUMORS;
D O I
10.1186/s13045-016-0278-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor. Case presentation: In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who achieved a clinical and radiological remission with PD-1 blockade. Conclusions: To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma
    Shirasawa, Masayuki
    Yoshida, Tatsuya
    Takayanagi, Daisuke
    Shiraishi, Kouya
    Yagishita, Shigehiro
    Sekine, Katsutoshi
    Kanda, Shintaro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Hamada, Akinobu
    Kohno, Takashi
    Yamamoto, Noboru
    Watanabe, Shun-ichi
    Ohe, Yuichiro
    Motoi, Noriko
    CLINICAL LUNG CANCER, 2021, 22 (04) : 282 - +
  • [42] Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold
    Qin, Mingze
    Cao, Qi
    Wu, Xia
    Liu, Chunyang
    Zheng, Shuaishuai
    Xie, Hongbo
    Tian, Ye
    Xie, Jun
    Zhao, Yanfang
    Hou, Yunlei
    Zhang, Xian
    Xu, Boxuan
    Zhang, Haotian
    Wang, Xiaobo
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 186
  • [43] Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
    Robert, Caroline
    Soria, Jean-Charles
    Eggermont, Alexander M. M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) : 2968 - 2971
  • [44] Countering antidrug antibodies to programmed cell death-1 blockade in mouse Pten-null prostate cancer
    De Velasco, Marco A.
    Kura, Yurie
    Sako, Noriko
    Ando, Naomi
    Fujita, Kazutoshi
    Nishimoto, Mitsuhisa
    Sakai, Kazuko
    Yoshimura, Kazuhiro
    Nozawa, Masahiro
    Hammond, Scott A.
    Dovedi, Simon J.
    Davies, Barry R.
    Nishio, Kazuto
    Uemura, Hirotsugu
    CANCER RESEARCH, 2023, 83 (07)
  • [45] Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
    Zhang, Xu
    Yang, Guozhen
    Su, Xiaodong
    Luo, Guangyu
    Cai, Peiqiang
    Zheng, Yating
    Bei, Ting
    Gao, Chan
    Huang, Mengli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
    Kim, Ji-Hyun
    Kim, Shinn-Young
    Shin, Eun-Young
    Jung, Ji-Han
    Choi, Hyun-Joo
    Jun, Kyong-Hwa
    ONCOLOGY LETTERS, 2019, 18 (03) : 2661 - 2669
  • [47] Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report
    Harada, Masanori
    Naoi, Hyogo
    Yasuda, Kazuyo
    Ito, Yutaro
    Kagoo, Namio
    Kubota, Tsutomu
    Ichijo, Koshiro
    Mochizuki, Eisuke
    Uehara, Masahiro
    Matsuura, Shun
    Tsukui, Masaru
    Koshimizu, Naoki
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [48] Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma
    Friedman, David
    Baird, Jason R.
    Young, Kristina H.
    Cottam, Benjamin
    Crittenden, Marka R.
    Friedman, Scott
    Gough, Michael J.
    Newell, Pippa
    HEPATOLOGY RESEARCH, 2017, 47 (07) : 702 - 714
  • [49] How representative are data from global trials on programmed death-1 blockade in melanoma?
    Schummer, Patrick
    Schilling, Bastian
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : 283 - 284
  • [50] Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
    Yang, Guozhen
    Su, Xiaodong
    Yang, Hong
    Luo, Guangyu
    Gao, Chan
    Zheng, Yating
    Xie, Wenzhuan
    Huang, Mengli
    Bai, Yuezong
    Wang, Zhiqiang
    Cai, Peiqiang
    He, Haoqiang
    Xiang, Jin
    Cai, Muyuan
    Zhang, Yijun
    Qu, Chunhua
    Fu, Jianhua
    Liu, Qianwen
    Hu, Yi
    Zhong, Jiudi
    Huang, Yuanheng
    Guo, Qiyu
    Zhang, Xu
    CANCER RESEARCH, 2021, 81 (13)